Skip to main content

Unable to load price data. Sorry.

¯\_(ツ)_/¯

ArQule, Inc. (NASDAQ:ARQL.DL)

CAPS Rating: No stars

A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.

Unable to load market data for this Ticker. Sorry.

¯\_(ツ)_/¯

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform
 

All-Star Players

0 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:ARQL.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

MrOneHundred (29.47)
Submitted February 24, 2013

I'm having a hard time reconciling a decent reason not to risk this stock with real money. In my opinion, at $2/share the company is poised to repeat miraculous gains in a relatively near future. Only twice in the past eleven years has this stock… More

scottbiddle64 (< 20)
Submitted January 15, 2013

Failure on clinical trials

NASDAQ:ARQL.DL VS S&P 500 (SPY)

NASDAQ:ARQL.DL Summary

  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about ARQL.DL.

No one has written a Pitch for ARQL.DL stock yet. Tell us why you think ARQL.DL will outperform or underperform against the market.

Leaderboard

Find the members with the highest scoring picks in ARQL.DL.

No players have picked ARQL.DL yet. Tell us why you think ARQL.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ARQL.DL.